OTLK - NASDAQ

Outlook Therapeutics, Inc.

OTLK·NASDAQ

$1.58

-0.94%

HealthcareBiotechnology

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$70.18M

EPS-1.7900

P/E Ratio-0.88

Earnings Date02/13/2026

18584.18B

Assets

64476477%

3Y+65144127.0%

5Y+94178094.0%

10Y+78394546.0%

50771.84B

Total Liabilities

49825230%

3Y+256537630.0%

5Y+300300628.0%

10Y+175643875.0%

-32187.66B

Total Equity

44046422%

3Y-368424520.0%

5Y-1138983150.0%

10Y+618972193.0%

Outlook Therapeutics, Inc. Funding & Solvency Profile

OTLK · NASDAQ

Current Assets

Cash & Cash Equivalents8083.09B

Net Receivables1490.93B

Inventory3338.40B

Other Current Assets4476.55B

Total Current Assets17389 B

Non-Current Assets

Property, Plant & Equipment225.51B

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets969.71B

Total Non-Current Assets1195 B

Total Assets

18584.18B

Financial Health Analysis

Current Ratio

0.38x

Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.

Working Capital

-28425636000000

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

94% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Outlook Therapeutics, Inc. Balance Sheet

OTLK • NASDAQ

Outlook Therapeutics, Inc. Balance Sheet	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020	Sep 2019	Sep 2018	Sep 2017	Sep 2016	Sep 2015	Sep 2014
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	8,083.1B	14.9M	23.4M	17.4M	14.5M	12.5M	8M	1.7M	3.2M	2.4M	2.3M	9.1M
Cash & Short-Term Investments	8,083.1B	14.9M	23.4M	17.4M	14.5M	12.5M	8M	1.7M	3.2M	2.4M	2.3M	9.1M
Net Receivables	1,490.9B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3M	4.3M
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20K	20K
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3M	4.3M
Inventory	3,338.4B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	10.1M	7M	5.4M	3.8M	1.2M	199.7K	1.3M	1.8M	1.8M
Other Current Assets	4,476.5B	12.5M	7.6M	0.0	324.0	0.0	1.7M	0.0	0.0	0.0	0.0	0.0
Total Current Assets	17,389B	27.4M	31M	27.5M	21.5M	17.9M	13.5M	3.3M	3.9M	5.7M	3.1M	15.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	225.5B	274.6K	26.2K	70.4K	275.1K	494.2K	3.2M	18.5M	16.1M	17M	8M	17.8M
Long-Term Investments	0.0	693.2K	793.9K	804.9K	853.7K	900K	0.0	0.0	0.0	216.1K	0.0	0.0
Other Non-Current Assets	969.7B	439.3K	501.3K	132K	174.6K	394.4K	457.5K	491K	740.4K	852.8K	447.6K	2.1M
Total Non-Current Assets	1,195.2B	1.4M	1.3M	1M	1.3M	1.8M	3.6M	19M	16.8M	18M	8.5M	19.8M
Other Assets	0.0	0.0	0.0	0.0	-451.0	449.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	18,584.2B	28.8M	32.3M	28.5M	22.8M	19.7M	17.1M	22.3M	20.7M	23.7M	11.6M	35M
LIABILITIES
CURRENT LIABILITIES
Total Payables	0.0	9.8M	8.4M	5.3M	4.1M	4.3M	2.3M	5.5M	13.3M	6.9M	11.6M	13.3M
Accounts Payable	10,192.4B	8M	6.6M	3.5M	2.2M	2.4M	2.3M	3.6M	11M	5.1M	11.6M	11.6M
Other Payables	0.0	1.9M	1.9M	1.9M	1.9M	1.9M	0.0	1.9M	2.4M	1.9M	0.0	1.8M
Accrued Expenses	0.0	3.2M	920K	2M	753.8K	579.6K	919.4K	2.3M	3.6M	4M	5.3M	2.9M
Short Term Debt	58.9B	29.4M	35.6M	10.9M	904.2K	3.7M	11.3M	17.9M	4.7M	5.2M	15M	15M
Capital Lease Obligations (Current)	0.0	50.9K	4.3K	38.7K	69.3K	4.2M	192.3K	520.8K	341.1K	977.2K	862.8K	862.8K
Tax Payables	302B	1.9M	1.9M	1.9M	1.9M	1.9M	1.9M	1.9M	2.4M	1.9M	1.6M	1.8M
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7M	3.1M	1.2M	1.5M	2M
Other Current Liabilities	45,755.7B	0.0	1.8M	1.5M	2.8M	5.1M	5.6M	4.2M	3.7M	2.2M	-12.4M	3M
Total Current Liabilities	45,814.6B	42.6M	46.7M	19.7M	6.8M	15.9M	20.3M	32M	28.7M	20.4M	20.2M	37M
NON-CURRENT LIABILITIES
Long Term Debt	188.8B	0.0	0.0	0.0	10.9M	904.2K	50.3K	98.5K	13.4M	2.2M	4.9M	4.9M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8M	4.5M	5.2M	6.3M	6.4M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5M	2.3M	0.0	4.7M	14.4M
Other Non-Current Liabilities	4,768.4B	59.1M	6.2K	57.1K	522.9K	70.8K	4.2M	4.7M	4.8M	761.3K	2.4M	284.7K
Total Non-Current Liabilities	4,957.2B	59.3M	6.2K	61.4K	11.5M	1M	7.6M	11.1M	22.7M	8.5M	14.9M	27.2M
Capital Lease Obligations	247.7B	297.8K	4.3K	43K	112.3K	4.2M	3.6M	3.5M	369.2K	1.3M	165K	2.1M
Total Liabilities	50,771.8B	101.9M	46.7M	19.8M	18.2M	16.9M	27.9M	43.1M	51.5M	28.9M	35.2M	64.3M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	32,300.6B	28,527.8B	22,811.5B	19,732.6B	5.4M	4.7M	2.9M	23,705.9B	9.4M	10.2M
Common Stock	538.9B	239.1K	2.6M	2.3M	1.8M	1.3M	286.1K	722.2K	249.3K	228K	39.8K	39.8M
Additional Paid-In Capital	0.0	470M	450.9M	415.4M	345.7M	291.3M	238.1M	190M	152.3M	142M	0.0	0.0
Retained Earnings	-605,709.8B	-543.3M	-467.9M	-408.9M	-342.9M	-289.7M	-254.5M	-216.3M	-186.2M	-147.4M	-45.2M	-94.1M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	-32,300.6B	417.7M	-22,811.5B	-19,732.6B	-1.1M	190.8M	-8.6M	-6M	-1.8M	-3.6M
Other Total Stockholders' Equity	572,983.2B	0.0	0.0	-28,527.8B	-167.0	-540.0	947.0	631.9K	0.0	-23,705.9B	15.4M	19.1M
Total Stockholders' Equity	-32,187.7B	-73.1M	-14.4M	8.7M	4.6M	2.8M	-10.8M	-20.8M	-30.7M	-5.2M	-23.5M	-28.6M
Total Equity	-32,187.7B	-73.1M	-14.4M	8.7M	4.6M	2.8M	-10.8M	-20.8M	-30.7M	-5.2M	-23.5M	-29.3M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1K	-654.4K
SUMMARY
Total Liabilities & Equity	18,584.2B	28.8M	32.3M	28.5M	22.8M	19.7M	17.1M	22.3M	20.7M	23.7M	11.6M	35M
Total Investments	0.0	693.2K	793.9K	804.9K	853.7K	900K	0.0	0.0	0.0	216.1K	0.0	0.0
Total Debt	247.7B	29.7M	35.6M	11M	11.9M	8.8M	14.9M	21.9M	18.4M	8.7M	15.2M	22M
Net Debt	-7,835.4B	14.8M	12.2M	-6.4M	-2.6M	-3.7M	6.9M	20.2M	15.2M	6.4M	12.8M	12.9M
Shares Outstanding	44,419,529	44,419,529	44,419,529	44,419,529	44,419,529	44,419,529	44,419,529	44,419,529	44,419,529	44,419,529	44,419,529	44,419,529

SEC Filings

OTLK - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-K 10-K 2025 FY FY	December 19, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 19, 2025	December 19, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 03, 2025	November 03, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 29, 2025	September 29, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 05, 2025	September 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 02, 2025	August 28, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 14, 2025	August 14, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 14, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 01, 2025	June 28, 2025	2025	View Filing

Showing 1 to 10 of 229 filings

Related Guides

Blog Categories

Continue your OTLK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.